Corbus Pharmaceuticals
CRBP
82 hedge funds and large institutions have $335M invested in Corbus Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 3 closing their positions.
7,271% more capital invested
Capital invested by funds: $4.54M → $335M (+$330M)
1,633% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 3
150% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 6
141% more funds holding
Funds holding: 34 → 82 (+48)
64.31% more ownership
Funds ownership: 17.01% → 81.31% (+64%)
3% more call options, than puts
Call options by funds: $3.2M | Put options by funds: $3.09M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$49.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$17.3M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.2M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
+$9.99M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$9.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$906K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$417K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$34.5K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$15.2K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$5.33K |
CRBP Hedge Fund Activity: Q1 2024 in Review
82 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q1 2024, worth a combined $335M — up 7,271% from $4.54M a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new CRBP positions and 3 closed out — a net gain of 49 holders — while 15 added to existing stakes and 6 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $49.9M. The largest seller was Sio Capital Management, exiting entirely with an estimated $906K sold.
- 82 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q1 2024, up from 34 in Q4 2023.
- Funds reported $335M of Corbus Pharmaceuticals stock for Q1 2024, up 7,271% quarter-over-quarter.
- 52 funds opened new Corbus Pharmaceuticals positions in Q1 2024 and 3 closed out, a net change of +49 holders.
- The largest Corbus Pharmaceuticals buyer in Q1 2024 was Cormorant Asset Management, an estimated $49.9M added.
- The largest Corbus Pharmaceuticals seller in Q1 2024 was Sio Capital Management, an estimated $906K sold.
Based on aggregated 13F filings for Q1 2024.